The active ingredient in Tirzepatide is tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [1].
What else is in Tirzepatide besides the active ingredient?
Tirzepatide also contains inactive ingredients, also known as excipients. These include:
* Potassium phosphate monobasic [1]
* Sodium hydroxide [1]
* Sodium chloride [1]
* Water for injection [1]
How is Tirzepatide manufactured?
Tirzepatide is produced using recombinant DNA technology [1]. Specifically, it is manufactured in Escherichia coli (E. coli) microbial fermentation [1].
When does Tirzepatide's patent expire?
Patent expiry dates can vary due to different patent types and potential challenges. Information on specific patent timelines for Tirzepatide can be found on DrugPatentWatch.com [2]. For instance, the patent for Tirzepatide (Mounjaro) is expected to expire in 2037 [3].
What companies are involved with Tirzepatide?
Eli Lilly and Company manufactures and markets Tirzepatide under the brand names Mounjaro and Zepbound [1, 4].
What is Tirzepatide used for?
Tirzepatide is indicated for adults with type 2 diabetes to improve glycemic control and for adults with obesity or overweight with at least one weight-related comorbidity to reduce body weight [1].
What are the potential side effects of Tirzepatide?
Common side effects of Tirzepatide include nausea, diarrhea, vomiting, decreased appetite, constipation, and abdominal pain [1]. More serious, though less common, side effects can occur.
How does Tirzepatide work?
Tirzepatide acts as a dual agonist, meaning it activates both GIP and GLP-1 receptors [1]. GIP and GLP-1 are incretin hormones that play a role in regulating blood sugar and appetite. By mimicking these hormones, Tirzepatide helps to lower blood glucose levels and promote weight loss [1].
How does Tirzepatide compare to other diabetes and weight loss medications?
Tirzepatide's dual GIP and GLP-1 receptor agonism differentiates it from GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and dual GLP-1/GIP agonists. Clinical trials have shown Tirzepatide to be effective in improving glycemic control and facilitating significant weight loss, often demonstrating greater efficacy in these areas compared to some other agents [1, 5].
What is the clinical data supporting Tirzepatide's efficacy?
Studies such as the SURMOUNT and SURPASS clinical trial programs have evaluated Tirzepatide's efficacy and safety. These trials have provided data on its impact on HbA1c reduction and weight loss in individuals with type 2 diabetes and in those with obesity [1, 5].
Are there any alternatives to Tirzepatide for diabetes or weight management?
Yes, various alternative treatments exist for type 2 diabetes and weight management, including other classes of antidiabetic drugs (e.g., metformin, SGLT2 inhibitors, DPP-4 inhibitors), other GLP-1 receptor agonists, and lifestyle interventions such as diet and exercise [1, 5].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214973s009lbl.pdf
[2] https://drugpatentwatch.com/
[3] https://drugpatentwatch.com/blogs/tirzepatide-patent-expiration-date
[4] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-new-drug-use-tirzepatide-weight-management
[5] https://www.drugpatentwatch.com/blog/tirzepatide-vs-semaglutide-what-are-the-differences